A Look At Immunome (IMNM) Valuation As Varegacestat Nears ASCO 2026 Spotlight And FDA NDA Filing [Yahoo! Finance]
Immunome, Inc. (IMNM)
Company Research
Source: Yahoo! Finance
Immunome (IMNM) is back in focus after announcing that Phase 3 data for its desmoid tumor drug candidate, varegacestat, will be featured in an oral session at the 2026 ASCO Annual Meeting. The company also plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second quarter of 2026, a step that moves this program closer to a potential commercial decision point. See our latest analysis for Immunome. The latest ASCO and FDA milestones come after a mixed trading stretch, with a 16.06% 1 month share price return helping offset an 8.93% 3 month decline and a very large 3 year total shareholder return. If you are interested in oncology names tied to similar themes, this is a good moment to look at other healthcare names using our screener for 33 healthcare AI stocks With IMNM trading at a discount to analyst targets and showing a very large 1-year total return, you have to ask: is there still a reasonable entry point here, or is the market already
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid TumorsBusiness Wire
- Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual MeetingBusiness Wire
- Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More [Yahoo! Finance]Yahoo! Finance
IMNM
Earnings
- 8/6/25 - Beat
IMNM
Sec Filings
- 4/24/26 - Form DEFA14A
- 4/24/26 - Form ARS
- 4/24/26 - Form DEF
- IMNM's page on the SEC website